Connect with others who understand.

sign up log in
About MyBCTeam

Tecentriq is a prescription drug approved by the Food and Drug Administration (FDA) to treat adult patients with triple-negative breast cancer (TNBC) in cases where surgery is not an option and the tumor is metastatic or locally advanced. Tecentriq may be prescribed in cases where breast cancer cells test positive for programmed cell death protein 1 (PD-L1). Tecentriq is also known by its drug name Atezolizumab. Tecentriq is prescribed in combination with chemotherapy drug Paclitaxel. Tecentriq was granted accelerated approval by the FDA based on results in clinical trials. The continued availability of the drug may depend on the results of further studies.

Between 10 and 15 percent of breast cancers are triple-negative, meaning that the cancer cells do not test positive for receptors for estrogen, progesterone, or human epidermal growth factor receptor 2 (HER2). The lack of receptors makes TNBC harder to target with treatments. PD-L1 is a protein that helps cancer cells evade the immune system. Tecentriq is a genetically engineered antibody (protein) designed to bind with PD-L1 expressed on tumor cells and tumor-infiltrating immune cells. Tecentriq is believed to work by allowing the immune system to identify and destroy cancer cells.

How do I take it?
Tecentriq is administered as an intravenous injection by a healthcare professional. For each 28-day cycle, Tecentriq is administered on days 1 and 15, and Paclitaxel is administered on days 1, 8, and 15.

Side effects
The FDA-approved label for Tecentriq lists common side effects including hair loss, fatigue, peripheral neuropathy (numbness or tingling in the hands and feet), nausea, diarrhea, constipation, cough, headache, abnormal blood cell counts, diminished appetite, and vomiting.

Rare but serious side effects listed for Tecentriq can include heart failure, lung damage, liver abnormalities, hepatitis, thyroid disorders, and severe infusion reactions.

For more details about this treatment, visit:

Tecentriq - Genentech

Triple Negative Breast Cancer: New Study Highlights the Promise and Challenges of Immunotherapy

Continue with Facebook
Sign up with your email
Already a Member? Log in